• Study reports abnormally high VTE and high bleed risk in critically ill COVID-19 patients and calls for more effective prevention strategies.
  • Clinicians at NHS hospitals are supporting the care of COVID-19 patients with the use of geko™ devices to reduce the risk of blood clots in the most at risk patients.
Learn more Contact us

Firstkind Ltd Joins the ABHI Innovation Hub at Dell Medical School


Firstkind Ltd, manufacturer of the geko™ device, is delighted to announce it has joined the ABHI Innovation Hub, a unique partnership between the Association of British HealthTech Industries (ABHI) and the Dell Medical School at The University of Texas at Austin.

The Hub offers the opportunity for Firstkind to be located within a world-class facility and to continue the development of future US business within an ecosystem of clinicians, investors and mentors. It also provides an infrastructure to strengthen geko™ device market access and clinician engagement in Texas and beyond.

The Hub is located within Dell Med’s Health CoLab, a new initiative that provides space and creates connections for companies who share the school’s mission to create healthier communities, starting in Austin and the surrounding areas. The Health CoLab directly supports the school by seeking out innovation that promotes health, enhances medical services, and increases care resources and access for people in this community in ways that can replicated to other communities.

Philip Kennedy, Chair of the ABHI, said: “The ABHI Innovation Hub at Dell Medical School will offer Firstkind a unique opportunity to collaborate in a truly world class facility. The Hub will support promising health technology innovation whilst looking to develop value-based healthcare for the benefit of patients in Texas, throughout the US and at home in the UK.”

Bernard Ross, CEO Firstkind Ltd, said: “The Dell Medical School has a strong focus on supporting health entrepreneurs and businesses. Being part of the Innovation Hub also means we will be able to participate in the ‘Texas Health Catalyst,’ a programme designed by the Dell Medical School to foster health research and advance innovation.”